Eye-disease-focused Acelyrin will be absorbed into immune-mediated disease specialist Alumis as part of an all-stock merger. The resulting company will continue under the Alumis name at the ...

LOS ANGELES, Feb. 20, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative ...

Acelyrin has punted the autoimmune drug prospect izokibep back to Affibody, completing a retreat from its former lead candidate that began with the axing of development in two diseases in August.

Biopharmaceutical companies Alumis and ACELYRIN said Thursday they have agreed to a merger which will see the combined company operate under the Alumis name with the current Alumis executive team.

Agoura Hills-based biotech firm Acelyrin Inc. agreed to merge with San Francisco-based Alumis Inc. in a deal valued at $320 million on February 6. Upon completion of the deal, which is expected to ...

ACELYRIN, Inc., a Los Angeles area-based, late-stage clinical biopharma, with additional operations in the San Francisco Bay area, has announced it is acquiring privately held ValenzaBio – which ...

MILWAUKEE--(BUSINESS WIRE)--Ademi & Fruchter LLP is investigating ACELYRIN (Nasdaq: SLRN) for possible breaches of fiduciary duty and other violations of law in its transaction with Alumis.

16:13 EST Acelyrin (SLRN) Inc trading halted, news pending Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment ...

Experts and advocates to provide important strategic input and clinical expertise as ACELYRIN completes its Phase 2 trial of lonigutamab in TED and prepares to initiate Phase 3 program in first ...

Alumis (ALUM) shares plunged ~17% in the premarket on Friday after the immunology-focused biopharma agreed to merge with its California-based rival Acelyrin (NASDAQ:SLRN) in an all-stock transaction.

Alumis (ALMS) and Acelyrin (SLRN) announced a definitive merger agreement under which Alumis and Acelyrin will merge in an all-stock transaction. Alumis and Acelyrin had cash, cash equivalents and ...